Research Summary

The goal of studies performed in my laboratory is to identify validated translational magnetic resonance spectroscopy (MRS) metabolic biomarkers of oncogenic transformation and response to existing and emerging anti-cancer therapeutics.

I am a Professor in the Department of Radiology and Biomedical Imaging at UCSF, a member of UCSF Brain Tumor Center and the Developmental Therapeutics Program at the UCSF HDFCCC, and a member of the California Institute for Quantitative Biosciences (QB3). I have an international track record using MRS in preclinical models of cancer to investigate cellular metabolism, and to identify and mechanistically validate novel MRS-based biomarkers. Our studies use established and engineered cell lines and animal models; multinuclear MRS approaches, including thermal equilibrium and hyperpolarized 13C MRS, 31P MRS and 1H MRS; and a range of biochemical, cell, and molecular biological assays, and our major focus is the study of brain tumors.

Current funded projects in the lab, in collaboration with members of the HDFCCC, the Brain Tumor Center, and the Developmental Therapeutics Program, focus on understanding the metabolic reprogramming of mutant IDH tumors and its significance for therapeutic targeting, metabolic imaging of response to targeted therapies in sensitive and resistant models, and imaging of response to emerging immunotherapies.

Research Funding

  • February 11, 2020 - January 31, 2025 - IMAGING TELOMERE MAINTENANCE MECHANISMS IN GLIOMAS, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA239288
  • April 1, 2016 - March 31, 2021 - Metabolic Imaging of Brain Tumor Response to Therapy, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA197254
  • February 5, 2013 - January 31, 2018 - Metabolic Reprogramming in Brain Tumors, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA172845
  • December 1, 2015 - November 30, 2017 - Hyperpolarized arginine imaging of inflammatory cells and their inhibition in GBM, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R21CA201453

Education

Hebrew University, Israel, BSc, 1981, Chemistry/Biochemistry
San Jose State University, California, MS, 1986, Chemistry
Weizmann Institute of Science, Israel, PhD, 1991, Chemical Physics

Honors & Awards

  • B.Sc. cum laude
  • Recipient of the Eshkol scholarship for Ph.D. studies
  • Recipient of an ICR fellowship (first three years at Institute at Institute of Cancer Research, UK)
  • International Society for Magnetic Resonance in Medicine (ISMRM) MR in Cancer Study Group - Secretary Elect 2006
  • International Society for Magnetic Resonance in Medicine (ISMRM) MR in Cancer Study Group - Secretary 2007

Selected Publications

  1. Viswanath P, Batsios G, Ayyappan V, Taglang C, Gillespie AM, Larson PEZ, Luchman HA, Costello JF, Pieper RO, Ronen SM Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.  View on PubMed
  2. Batsios G, Taglang C, Cao P, Gillespie AM, Najac C, Subramani E, Wilson DM, Flavell RR, Larson PEZ, Ronen SM, Viswanath P Imaging 6-Phosphogluconolactonase Activity in Brain Tumors In Vivo Using Hyperpolarized δ-[1-13C]gluconolactone.  View on PubMed
  3. Radoul M, Hong D, Gillespie AM, Najac C, Viswanath P, Pieper RO, Costello JF, Luchman HA, Ronen SM Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma.  View on PubMed
  4. Viswanath P, Batsios G, Mukherjee J, Gillespie AM, Larson PEZ, Luchman HA, Phillips JJ, Costello JF, Pieper RO, Ronen SM Non-invasive assessment of telomere maintenance mechanisms in brain tumors.  View on PubMed
  5. Subramani E, Radoul M, Najac C, Batsios G, Molloy AR, Hong D, Gillespie AM, Santos RD, Viswanath P, Costello JF, Pieper RO, Ronen SM Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.  View on PubMed
  6. Jones LE, Hilz S, Grimmer MR, Mazor T, Najac C, Mukherjee J, McKinney A, Chow T, Pieper RO, Ronen SM, Chang SM, Phillips JJ, Costello JF Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma.  View on PubMed
  7. Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.  View on PubMed
  8. Batsios G, Najac C, Cao P, Viswanath P, Subramani E, Saito Y, Gillespie AM, Yoshihara HAI, Larson P, Sando S, Ronen SM In vivo detection of ?-glutamyl-transferase up-regulation in glioma using hyperpolarized ?-glutamyl-[1-13C]glycine.  View on PubMed
  9. Chung BT, Chen HY, Gordon J, Mammoli D, Sriram R, Autry AW, Le Page LM, Chaumeil MM, Shin P, Slater J, Tan CT, Suszczynski C, Chang S, Li Y, Bok RA, Ronen SM, Larson PEZ, Kurhanewicz J, Vigneron DB First hyperpolarized [2-13C]pyruvate MR studies of human brain metabolism.  View on PubMed
  10. Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.  View on PubMed
  11. Najac C, Radoul M, Le Page LM, Batsios G, Subramani E, Viswanath P, Gillespie AM, Ronen SM In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma.  View on PubMed
  12. Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI.  View on PubMed
  13. Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, Gallagher FA, Keshari KR, Kjaer A, Laustsen C, Mankoff DA, Merritt ME, Nelson SJ, Pauly JM, Lee P, Ronen S, Tyler DJ, Rajan SS, Spielman DM, Wald L, Zhang X, Malloy CR, Rizi R Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology.  View on PubMed
  14. Taglang C, Korenchan DE, von Morze C, Yu J, Najac C, Wang S, Blecha JE, Subramaniam S, Bok R, VanBrocklin HF, Vigneron DB, Ronen SM, Sriram R, Kurhanewicz J, Wilson DM, Flavell RR Late-stage deuteration of 13C-enriched substrates for T1 prolongation in hyperpolarized 13C MRI.  View on PubMed
  15. Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.  View on PubMed
  16. Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.  View on PubMed
  17. Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.  View on PubMed
  18. Guglielmetti C, Najac C, Didonna A, Van der Linden A, Ronen SM, Chaumeil MM Hyperpolarized 13C MR metabolic imaging can detect neuroinflammation in vivo in a multiple sclerosis murine model.  View on PubMed
  19. Roy S, Leidal AM, Ye J, Ronen SM, Debnath J Autophagy-Dependent Shuttling of TBC1D5 Controls Plasma Membrane Translocation of GLUT1 and Glucose Uptake.  View on PubMed
  20. Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, Olson MP, Molinaro AM, Berger MS, Kurhanewicz J, Ronen SM, Chang SM, Nelson SJ Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.  View on PubMed

Go to UCSF Profiles, powered by CTSI